Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Tolerability of Intravitreal TK001(Recombinant Humanized Anti-VEGF Monoclonal Antibody) in Subjects With Neovascular Age-Related Macular Degeneration

NCT02613559 is registered in ClinicalTrials.gov with Jiangsu T-Mab Biopharma Co.,Ltd as lead sponsor.

NCT NCT02613559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02613559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Tolerability of Intravitreal TK001(Recombinant Humanized Anti-VEGF Monoclonal Antibody) in Subjects With Neovascular Age-Related Macular Degeneration
Lead sponsor
Jiangsu T-Mab Biopharma Co.,Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2015
Completion date
September 30, 2018
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration